Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…
Headline
The Substance Abuse and Mental Health Services Administration announced March 6 that it will award $69.1 million in grants for mental health and suicide…
Headline
The Food and Drug Administration March 5 issued a request for information seeking public comments on potential new standards for in-home opioid disposal…
Headline
The Centers for Medicare & Medicaid Services has released a toolkit that outlines strategies for states to strengthen access to behavioral health services…
Blog
Digital tools are improving access to behavioral health care at a time when demand is increasing. Individuals can use digital access points to better…
Headline
The Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology announced the selection of nine pilots as…